154 related articles for article (PubMed ID: 36287631)
1. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
Kizilocak H; Marquez-Casas E; Malvar J; Young G
Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
5. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
Schultz NH; Glosli H; Bjørnsen S; Holme PA
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
[TBL] [Abstract][Full Text] [Related]
6. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
Kenet G; Fujii T
Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
Holmström M; Tran HT; Holme PA
Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
13. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
Bravo MI; Raventós A; Pérez A; Costa M; Willis T
J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
[TBL] [Abstract][Full Text] [Related]
14. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
17. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
Schneiderman J; Nugent DJ; Young G
Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
[TBL] [Abstract][Full Text] [Related]
18. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
19. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
[TBL] [Abstract][Full Text] [Related]
20. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Klintman J; Astermark J; Berntorp E
Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
